Article
Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world.
Pharmacogenetics - 1 Oct 1999
Xie H G, Stein C M, Kim R B, Wilkinson G R, Flockhart D A, Wood A J
Abstract excerpt
Impaired S-mephenytoin 4'-hydroxylation is a well-described genetic polymorphism affecting drug metabolism in humans. The reported population prevalence of the CYP2C19 poor metabolizer phenotype in Caucasians of European descent has been described as ranging from 0.9% to 7.7%. To address the question of whether the difference in the frequency of poor metabolizers represents an ethnic genetic microheterogeneity in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.